Latest Breaking News On - Roivant sciences - Page 8 : comparemela.com

Gynecology Collaboration, R&D, and Licensing Deals Trends

Gynecology Collaboration, R&D, and Licensing Deals Trends
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMybiotics pharmaBiosyent pharmaMayne pharmaUlisse biomedValeo pharmaCocrystal pharmaPierre fabreEurofins lifecodexxMicrobix biosystemsAsieris meditechIndegene lifesystemsGenea biomedxXbrane bioscienceMillicent pharmaInserm transfert

Institutional investors are Roivant Sciences Ltd s (NASDAQ:ROIV) biggest bettors and were rewarded after last week s US$290m market cap gain

Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their.

Dan orenRoivant sciences ltdRoivant sciencesInstitutional ownership tell us about roivant sciencesRoivant scienceInstitutional investorsNstitutional ownershipNsider ownershipStock price

Roivant Sciences Ltd (NASDAQ:ROIV) Receives $16 90 Consensus Target Price from Analysts

Roivant Sciences Ltd (NASDAQ:ROIV) Receives $16 90 Consensus Target Price from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Eric venkerAnalyst recommendations for roivant sciencesSecurities exchange commissionNews ratings for roivant sciences dailyAllspring global investments holdingsInvestment advisersPath wealth partnersRoivant sciences stockWolfe researchRoivant sciences ltdInstitutional investors weigh in on roivant sciencesCovestor ltdHeadlands technologiesGoldman sachs groupRoivant sciencesGet free report

Roivant Sciences Ltd (NASDAQ:ROIV) Receives $16 90 Average PT from Brokerages

Roivant Sciences Ltd (NASDAQ:ROIV) Receives $16 90 Average PT from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Piper sandlerEric venkerAnalyst recommendations for roivant sciencesHeadlands technologiesInvestment advisersRoivant sciences tradingRoivant sciences ltdRoivant sciencesGoldman sachs groupNews ratings for roivant sciences dailyPath wealth partnersAllspring global investments holdingsCovestor ltdDeutsche bank aktiengesellschaftRoivant sciences company profileInstitutional trading of roivant sciences

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

LONG BEACH, Calif. & BASEL, Switzerland (BUSINESS WIRE) Apr 29, 2024

United statesTodd zavodnickAngela salerno robinDrug administrationRoivant sciencesDermavant sciencesDermavant sciences incDermavant sciences gmbLinkedin dermavant sciencesSupplemental new drug applicationPrescription drug user fee actChief executive officerPrescribing informationAll rightsVice presidentMedia relations